基本信息
浏览量:3
职业迁徙
个人简介
Dr. Wang initiated a program for clinical multi-omics analysis for human cancers after he joined. In 2010, Dr. Wang developed the world’s first mutant protein detection and quantification platform, “MT-SRM”, a pipeline capable of quantifying protein copy numbers in a single human cell with mass spectrometry after NGS targeted sequencing. Next, Dr. Wang developed the first scalable proteomics biomarker discovery and validation platform, “SAFE-SRM”, which launched the use of mass spectrometry-based proteomics into the clinical setting. He systematically evaluated and compared the benefits and problems of utilizing different omics technologies in cancer early detection. In 2019, he invented the pipeline “MANA-SRM” and “Valid-NEO” for direct detection and quantification of neoantigens from cells and minute quantities of human tumor tissue, which has paved the way for a new generation of personalized cancer therapeutics. Recently, he developed a comprehensive clinical proteomics molecular diagnostics platform, Complete360®, which enables multi-omics-based quantification of a large number of biomarkers in human body fluid samples. On a minor note, he also invented and patented “DEEPER-Seq”, the world’s only barcoded single-stranded library and dual RNA probe-based targeted sequencing platform for ultra-rare mutation calling with Next Generation Sequencing (NGS). Dr. Wang’s research has been featured in major media outlets, including Genomeweb, Newswire, ScienceDaily, and numerous major media from China as well as traditional high-impact peer-reviewed journals.
Through Complete Omics Inc., Dr. Wang is working to break the boundaries between different fields in medicine and the life sciences and to comprehensively leverage the features of omics technologies to achieve improved personalized disease management and precision medicine.
Through Complete Omics Inc., Dr. Wang is working to break the boundaries between different fields in medicine and the life sciences and to comprehensively leverage the features of omics technologies to achieve improved personalized disease management and precision medicine.
研究兴趣
论文共 49 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Xueqian Zhuang,Simon Joost,Qing Wang, Melissa Blum, Selena Ding,Zhuxuan Li,Yingqian Zhan,Richard Koche,Emily Wong,Tuomas Tammela
CANCER RESEARCHno. 2 (2023)
Yan Xiong,Jaiprakash Sharma,Meggie N. Young,Wen Xiong, Ali Jazayeri, Karl F. Poncha,Ma. Xenia G. Ilagan,Qing Wang,Hui Zheng,Nicolas L. Young,Marco Sardiello
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Cell Proliferation (2023)
引用1浏览0引用
1
0
Yuri Laguna Terai,Chun Huang,Baoli Wang,Xiaonan Kang, Jing Han,Jacqueline Douglass,Emily Han-Chung Hsiue,Ming Zhang, Raj Purohit, Taylor deSilva,Qing Wang
CANCER RESEARCHno. 4 (2022)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn